LOGIN  |  REGISTER
Surmodics
Assertio

Teleflex to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 26, 2023 | Last Trade: US$206.71 0.00 0.00

WAYNE, Pa., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 42nd Annual J.P. Morgan Healthcare Conference at The Westin St. Francis in San Francisco, California, on Tuesday, January 9, 2024, at 3:00 p.m. (PT).

A live audio webcast of the conference presentation, along with the accompanying slide presentation, will be available on the investor section of the Teleflex website at teleflex.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, QuikClot®, LMA®, Pilling®, Rüsch®, UroLift® and Weck® – trusted brands united by a common sense of purpose.

Contacts:
Teleflex
Lawrence Keusch
Vice President, Investor Relations and Strategy Development
This email address is being protected from spambots. You need JavaScript enabled to view it.
610-948-2836

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB